Abstract #2809

Evaluation of neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR metabolomics

Leslie R. Euceda¹, Tonje H. Haukaas^1,2, Guro F. Giskeødegård¹, Riyas Vettukattil¹, Geert Postma³, Laxmi Silwal-Pandit^2,4, Jasper Engel⁵, Lutgarde M.C. Buydens³, Anne-Lise Børresen-Dale^2,4, Olav Engebraaten⁶, and Tone F. Bathen^1,2

¹Department of Circulation and Medical Imaging, The Norwegian University of Science and Technology, Trondheim, Norway, ²K.G. Jebsen Center for Breast Cancer Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ³Institute for Molecules and Materials, Radboud University Nijmegen, Nijmegen, Netherlands, ⁴Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway, ⁵NERC Biomolecular Analysis Facility Metabolomics Node (NBAF-B), School of Biosciences, University of Birmingham, Birmingham, United Kingdom, ⁶Department of Oncology, Department of Tumor Biology, Oslo University Hospital, Oslo, Norway

This study used HR MAS magnetic resonance based metabolic profiles from breast tumor tissue to explore the metabolic changes occurring as an effect of overall neoadjuvant therapy, discriminate therapy responders from nonresponders, and determine metabolic differences between patients receiving or not receiving the antiangiogenic drug bevacizumab. Changes as an effect of chemotherapy were detected and responders were successfully discriminated from nonresponders after treatment, showing potential for assessment of patient benefit to treatment and the understanding of underlying mechanisms affecting response. Although metabolic differences based on bevacizumab administration were not prominent, glutathione was identified to be possibly affected by the drug.

This abstract and the presentation materials are available to members only; a login is required.

Join Here